Rushed approval bypassed carcinogenicity and full reproductive toxicity studies, Pfizer’s post-marketing data logged ~1,200 suspected deaths in two months, and Germany’s PEI reported 2,133 vaccine-linked fatalities that—at a 1–10% pharmacovigilance capture rate—extrapolate to roughly 20,000–60,000 actual deaths.

Full-year 2026 revenue is projected at $59.5–62.5 billion as vaccine sales decline, with the non-COVID portfolio growing about 9% operationally. Q4 revenue of $17.56 billion was down 1.2% year-over-year but beat top-line estimates, and organic revenue has averaged roughly 10% annual growth over the last two years. Adjusted operating margin widened by about 17.8 percentage points, and free cash flow of around $8.5–9.1 billion falls just short of covering dividend payments, prompting a $7.2 billion cost-savings program through 2027. Acquisitions of Seagen and Metsera bolster oncology and obesity pipelines, with double-digit growth expected for recently launched and acquired products.

Emergency authorizations waived long-term toxicology and carcinogenicity tests for Pfizer’s Comirnaty shot, triggering claims of legal violations, underreporting controversies over vaccine-linked deaths, and calls for outright bans. Meanwhile, EU courts have enforced COVID-19 vaccine supply contracts, CureVac/GSK have licensed mRNA rights to Pfizer/BioNTech, and China-focused R&D partnerships are reshaping global vaccine distribution and manufacturing footprints.

Rushed mRNA approvals and underreporting concerns from an ex-Pfizer toxicologist spark narrative skepticism and calls for safety moratoriums, countered by assertive government assurances of rigorous testing and rare side effects. Investor enthusiasm on Pfizer’s post-COVID pipeline and perceived undervaluation is tempered by disappointment in flat 2026 guidance and declining COVID-vaccine revenue, leaving overall sentiment cautious.